Startseite>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Calcium Channel>>Lercanidipine

Lercanidipine

Katalog-Nr.GC17625

Lercanidipin ist ein lipophiler Dihydropyridin-Calcium-Kanalblocker der dritten Generation (DHP-CCB).

Products are for research use only. Not for human use. We do not sell to patients.

Lercanidipine Chemische Struktur

Cas No.: 100427-26-7

Größe Preis Lagerbestand Menge
5mg
52,00 $
Auf Lager
50mg
181,00 $
Auf Lager
100mg
269,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lercanidipine is a calcium channel blocker of the dihydropyridine class.Target: Calcium ChannelLercanidipine is a calcium channel blocker of the dihydropyridine class, which works by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. Lercanidipine was effective and well-tolerated in patients with mild-to-moderate hypertension in the daily practice. The effectiveness and safety of the drug were independent of the degree of cardiovascular risk [1, 2].

References:
[1]. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70.
[2]. Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7.

Bewertungen

Review for Lercanidipine

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lercanidipine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.